SCHEMBL982676

SCHEMBL982676

CCOC(=O)c1nn(C)cc1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
MEN1 O00255 1/20 0.57
ADORA3 P0DMS8 1/20 0.54
ADORA2A P29274 1/20 0.54
ADORA1 P30542 1/20 0.54
MAPT P10636 2/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
NPC1 O15118 5/20 0.50
RAB9A P51151 4/20 0.50
KDM4E B2RXH2 3/20 0.50
GLA P06280 1/20 0.49
BAZ2B Q9UIF8 1/20 0.49
BAZ2A Q9UIF9 1/20 0.49
TP53 P04637 2/20 0.48
HSD17B10 Q99714 2/20 0.48
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18869612 0.92 KMT2A (0.51) KMT2AMEN1ADORA3ADORA2AADORA1
SCHEMBL2516609 0.84 ADORA2A (0.55) KMT2AMEN1ADORA3ADORA2AADORA1
SCHEMBL1459312 0.84 ADORA2A (0.55) ADORA3ADORA2AADORA1NPC1RAB9A
SCHEMBL3676305 0.83 ADORA2A (0.54) KMT2AMEN1ADORA3ADORA2AADORA1
SCHEMBL18362240 0.81 ADORA2A (0.59) ADORA3ADORA2AADORA1NPC1RAB9A
SCHEMBL17375095 0.81 NPC1 (0.64) KMT2AMEN1ADORA3ADORA2AADORA1
SCHEMBL19312686 0.81 ADORA2A (0.52) KMT2AMEN1ADORA3ADORA2AADORA1
SCHEMBL15277560 0.81 ADORA2A (0.52) KMT2AMEN1ADORA3ADORA2AADORA1
SCHEMBL2385094 0.81 ADORA2A (0.52) ADORA3ADORA2AADORA1NPC1RAB9A
SCHEMBL4511380 0.81 ADORA2A (0.49) KMT2AMEN1ADORA3ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 US disclosed
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-02-22 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-02 US disclosed
CN-114502158-A IRAK degradation agent and application thereof 凯麦拉医疗公司 2022-05-13 CN disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 EP disclosed
US-20210101885-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. 2021-04-08 US disclosed
US-9556149-B2 Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor ARENA PHARMACEUTICALS, INC. (US) 2017-01-31 US disclosed
US-9556149-B2 Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor ARENA PHARMACEUTICALS, INC. (US) 2017-01-31 US disclosed
US-20150045372-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. 2015-02-12 US disclosed
US-20150045372-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. 2015-02-12 US disclosed
US-20150045372-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. 2015-02-12 US disclosed
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2011-01-27 US disclosed
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2011-01-27 US disclosed
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2011-01-27 US disclosed
WO-2009123714-A2 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2009-10-08 WO disclosed
WO-2009123714-A2 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR ARENA PHARMACEUTICALS, INC. (US) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 KMT2A 289/4885MEN1 4533/4885ADORA3 3372/4885
US-20150045372-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR HTR5A, HTR2A, HTR3A KMT2A 2827/4885MEN1 2851/4885ADORA3 43/4885
US-20210101885-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR HTR5A, HTR2A, HTR3A KMT2A 2827/4885MEN1 2851/4885ADORA3 43/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 KMT2A 605/4885MEN1 4755/4885ADORA3 1866/4885
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MEN1 4055/4885ADORA3 3445/4885
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF IRAK4, IRAK2, IRAK3 KMT2A 295/4885MEN1 3785/4885ADORA3 3975/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MEN1 4055/4885ADORA3 3445/4885
US-20110021538-A1 PROCESSES FOR THE PREPARATION OF PYRAZOLE DERIVATIVES USEFUL AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR HTR5A, HTR2A, HTR3A KMT2A 2827/4885MEN1 2851/4885ADORA3 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.